Physician

Adam Michael Rosen, MD

According to 2025 Medicare claims, Adam Rosen, MD (NPI: 1407831076) practices rheumatology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is ARTHRITIS & RHEUMATISM ASSOCIATES PL (NPI: 1942284849; TIN: 593337044) and primary practice location at 33756-3912. Rosen is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290) and Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Rosen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 489 traditional Medicare patients, billed 609,013 HCPCS/CPT codes, and received $6,156,738 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,037 prescription claims across 450 beneficiaries totaling $998,079 in drug costs, led by Enbrel Mini (Etanercept). Open Payments data shows 127 records totaling $29,470. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $3,742,825 and ending at $6,156,738. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	624	324,103	$3,742,825
2016	717	376,218	$4,179,035
2017	742	492,912	$5,052,640
2018	586	378,300	$4,431,403
2019	581	355,610	$4,592,833
2020	629	427,651	$5,200,798
2021	687	329,061	$3,910,909
2022	629	298,366	$3,365,441
2023	518	327,773	$4,060,245
2024	489	609,013	$6,156,738

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	473	4,028	$1,330,910
2016	597	4,541	$1,945,312
2017	572	4,071	$2,215,264
2018	479	3,250	$2,281,515
2019	438	2,723	$2,548,916
2020	443	2,585	$1,638,506
2021	527	2,587	$1,807,288
2022	438	2,176	$1,638,175
2023	390	1,791	$1,153,912
2024	450	2,037	$998,079

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	226	1,679	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	401	1,187	$91
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	231	859	$51
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	395	1,038	$13
36415	Insertion of needle into vein for collection of blood sample	247	410	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Mini	Etanercept	20	560	$142,875
Humira(Cf) Pen	Adalimumab	13	384	$118,876
Xeljanz Xr	Tofacitinib Citrate	13	390	$73,866
Taltz Autoinjector	Ixekizumab	11	308	$73,722
Otezla	Apremilast	13	390	$66,287

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$29,470	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Michael Rosen, MD?

Tedicare shows public-source Medicare data for Adam Michael Rosen, MD (NPI 1407831076), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Michael Rosen, MD have ACO affiliation data?

Adam Michael Rosen, MD is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290) and Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to Adam Michael Rosen, MD?

Adam Michael Rosen, MD is linked to ARTHRITIS & RHEUMATISM ASSOCIATES PL (billing NPI 1942284849) in the available physician profile data.

Does Adam Michael Rosen, MD have Open Payments data?

Adam Michael Rosen, MD has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.